# The INVEST study (Infusion VErsus STimulation), a cost-effectiveness analysis of the treatment of advanced Parkinson's disease comparing Continuous Levodopa Infusion to the traditional standard treatment Deep Brain Stimulation

https://neurodegenerationresearch.eu/survey/the-invest-study-infusion-versus-stimulation-a-cost-effectiveness-analysis-of-the-treatment-of-advanced-parkinson%c2%92s-disease-comparing-continuous-levodopa-infusion-to-the-traditional-standard-t/

# **Principal Investigators**

Dr. J.M. Dijk

Institution

Academisch Medisch Centrum

Contact information of lead PI Country

Netherlands

# Title of project or programme

The INVEST study (Infusion VErsus STimulation), a cost-effectiveness analysis of the treatment of advanced Parkinson's disease comparing Continuous Levodopa Infusion to the traditional standard treatment Deep Brain Stimulation

Source of funding information

7onMw

Total sum awarded (Euro)

€ 400,000

Start date of award

01/10/2014

Total duration of award in years

## The project/programme is most relevant to:

Parkinson's disease & PD-related disorders

## **Keywords**

### **Research Abstract**

OBJECTIVE(S)/RESEARCH QUESTION(S) To realize a cost-effective treatment strategy in advanced Parkinson's disease (PD). Do additional costs of the frequently used Continuous Levodopa Infusion (CLI) lead to a sufficient increase in quality of life, compared to traditional standard treatment with Deep Brain Stimulation (DBS)?

HYPOTHESIS CLI is no cost-effective therapy.

STUDY DESIGN Prospective, randomized, open label multicenter trial, with two additional patient preference treatment arms ("patient preference randomized trial").

STUDY POPULATION(S)/DATASETS Patients with PD who, despite optimal pharmacological treatment, have severe response fluctuations, dyskinesias, painful dystonia, or bradykinesia. A total of 66 patients will be randomized, at least120 patients will be included in the patient preference arms.

INTERVENTION For CLI treatment, a tube will be placed in the jejunum via a percutaneous endoscopic gastrostomy (PEG). The tube is connected to an external pump that delivers the Levodopa-gel.

# Lay Summary Further information available at:

### Types:

Investments > €500k

### **Member States:**

Netherlands

### Diseases:

Parkinson's disease & PD-related disorders

# Years:

2016

### **Database Categories:**

N/A

### **Database Tags:**

N/A